California-based Integrated Biosciences, a biotechnology startup pioneering the use of advanced technology and synthetic biology to develop novel therapeutics for age-related illnesses, announced it has secured $17.2 million in seed funding to advance treatment for healthier aging.
Felix Wong and Max Wilson co-founded Integrated Biosciences in September 2022 to develop cellular rejuvenation therapies using a combination of small molecules and optogenetics.
The company aims to achieve healthier aging using machine learning and synthetic biology to control critical cell functions such as response to stress, enabling doctors to treat osteoarthritis, cancer, diabetes, neurodegeneration, and other age-related medical conditions.
The seed round was backed by a consortium of companies spearheaded by Sutter Hill Ventures, with significant contributions from notable investors, including Root Ventures, Illumina Ventures Labs, Civilization Ventures, Lifespan Vision Ventures, SH Fund (Sabrina Hahn), Overlap Holdings, Conscience VC, Reinforced Ventures, Mission BioCapital, Polymath Capital, Vijay Pandurangan and Michael Stoppelman.
As part of the partnership deal, Keith Loebner, Ph. D., was appointed to the company’s Board, with Uri Alon, Ph. D., Wendy B. Young, Ph. D., and Karl Sylvester, M. D., taking advisory positions.
According to a statement by Felix Wong, CO-founder and CEO of Integrated Biosciences, the new capital infusion would help the company to upscale synthetic biology and improve its AI platform.
